真理不屈於環境，信念永存於堅持
【床位入院 Admission】
□ 管路確認：軟針(IV)、鼻胃管、尿管位置與固定
□ 生命徵象：測量基礎 VS (含體重)
□ 系統 Order：醫囑核對 (藥物、飲食、檢查)
□ 衛教事項：病房規範、呼叫鈴、防跌倒
□ 家屬聯繫：主要照護者資訊確認
【床位出院 Discharge】
□ 行政結算：出院帶藥、相關證明文件
□ 衛教指引：回診時間、傷口照護、服藥指引
□ 物品清點：健保卡、身分證、私人隨身物品
□ 系統流程：出院醫囑輸入、通知傳送人員
【緊急轉入 ICU】
□ 數據交接：最後 VS、給藥紀錄、液體平衡
□ 管路包備：氧氣瓶、袋裝點滴、監視器確認
□ 家屬聯繫：告知轉送資訊、ICU 接手窗口
□ 病況彙整：轉出前的病情變化摘要
【轉地下室 Death】
□ 禮儀處置：移除管路(按醫囑)、清潔、更衣
□ 物品清理：貴重物品請家屬簽名領回
□ 文件處理：死亡證明書開立、病歷總結
□ 後續流程：通知傳送人員、確認地下室交接
【肝硬化病情監測與惡化預警 (Clinical Alert)】
1. 生理指標監測 (Biochemical Markers):
● Serum NH3 (血氨):
- 正常參考值: < 50-80 μg/dL (依院端標準)。
- 警訊: 持續攀升或 > 100 μg/dL。
- 風險: 肝性腦病變 (肝昏迷)、意識障礙、躁動。
● PT / INR (凝血功能):
- 警訊: INR > 1.5 - 1.7 且持續延長。
- 風險: 肝細胞急性壞死、急性食道靜脈曲張大出血 (EV Bleeding)。
● Albumin (白蛋白):
- 警訊: < 2.8 - 3.0 g/dL。
- 風險: 嚴重腹水、全身水腫、自發性腹膜炎 (SBP)、肺部擴張不全。
2. 肝昏迷臨床分級 (Child-Pugh Score 關鍵項):
● Grade I: 睡眠倒錯、注意力不集中。
● Grade II: 語無倫次、明顯撲翼性震顫 (Asterixis)。
● Grade III: 極度嗜睡 (Somnolent) 但對聲音有反應。
● Grade IV: 深度昏迷 (Coma)。
3. 護理防禦要點 (Nursing Interventions):
● 腸道管理: 監測 Lactulose 效果，維持每日 2-3 次軟便 (排除腸道氨)。
● 安全防護: 高跌倒風險！凝血功能差，嚴防碰撞導致內出血。
● 感染防範: 注意 SpO2 與痰液，預防肝肺症候群併發吸入性肺炎。
● 出血觀察: 監測有無解黑便 (Melena) 或嘔血跡象。
def generate_four_score_order(eye, motor, brainstem, respiration):
"""
生成 FOUR Score 專業醫囑描述
"""
total = eye + motor + brainstem + respiration
# FOUR 指數各項定義 (人話翻譯)
summary = f"FOUR Score: E{eye}M{motor}B{brainstem}R{respiration}, Total: {total}/16"
order_text = f"請醫師根據以下數據調整醫囑：\n{summary}\n"
order_text += "備註：本單位已採用 FOUR Score 進行神經學評估，聽不懂請自行查閱最新重症護理指引。"
return order_text
# 範例：一個插管且腦幹反射尚存的病人
print(generate_four_score_order(eye=2, motor=3, brainstem=4, respiration=2))
醫療縮寫,臨床意義,對家屬的「人話」解釋
Code Blue,心肺功能停止,「病人現在突然沒呼吸心跳了，我們正在全力急救。」
Intubation,氣管內插管,「他的呼吸太喘、撐不住了，我們必須幫他插管、接上呼吸器代替他呼吸。」
DNR,放棄急救同意書,「如果病人到最後撐不住，我們是不是不要再讓他受苦（壓胸、電擊），讓他平靜地走？」
Septic Shock,敗血性休克,「病人的細菌感染太嚴重，毒素流進血液，導致血壓掉到危險邊緣，器官快要撐不住了。」
GCS 下降,昏迷指數下降,「病人的意識越來越不清楚，現在叫他也沒反應，代表大腦或身體狀況在惡化。」
Transfer to ICU,轉入加護病房,「病房現在的儀器不夠用了，我們要把他轉到加護病房，讓專門的團隊 24 小時盯著他。」
【Interaction: Warfarin & Antibiotics】
1. Mechanism: Displacement from albumin binding or inhibition of Cytochrome P450 (CYP) enzymes.
2. High-Risk Agents: Quinolones, Macrolides, and Sulfonamides (Baktar).
3. Clinical Impact: Elevated INR, increased risk of spontaneous bleeding (ICH, GI bleeding).
4. NP Intervention: Monitor INR frequently, consider prophylactic dose reduction, and switch to safer antibiotic options if possible.
【Interaction: Diuretics & Digoxin/Anti-arrhythmics】
1. Mechanism: Hypokalemia (induced by Loop diuretics like Lasix) sensitizes the myocardium to Digoxin.
2. Clinical Impact: Digoxin toxicity (N/V, blurred vision, life-threatening arrhythmias).
3. QT Prolongation: Combined use of Macrolides and certain antipsychotics (e.g., Haloperidol) increases risk of Torsades de Pointes (TdP).
4. NP Intervention: Monitor Serum K+ and Mg2+ levels; perform baseline and follow-up ECG to measure QTc intervals.
【Interaction: Statins & CYP Inhibitors】
1. Mechanism: Inhibition of CYP3A4 leads to elevated Statin serum levels.
2. Culprits: Grapefruit juice, Amiodarone, Diltiazem, and some Antifungals.
3. Clinical Impact: Rhabdomyolysis (muscle pain, tea-colored urine, acute renal failure).
4. NP Intervention: Educate patient on diet; assess CPK levels if muscle pain is reported.
【Sepsis Management - SSC 2021 Guidelines】
1. Implementation of Hour-1 Bundle: Initial lactate level measurement, obtaining blood cultures prior to administration of broad-spectrum antibiotics.
2. Fluid Resuscitation: For patients with sepsis-induced hypoperfusion or lactate ≥4 mmol/L, administer at least 30 mL/kg of IV crystalloid fluid within the first 3 hours.
3. Vasopressors: If MAP remains <65 mmHg despite fluid resuscitation, initiate norepinephrine as the first-line vasopressor.
4. Continuous Monitoring: Re-assess fluid status and tissue perfusion (MAP, Urine Output, Lactate clearance).
【AECOPD Management - GOLD 2024 Guidelines】
1. Oxygen Therapy: Target SpO2 maintained at 88-92% to prevent hypercapnic respiratory failure.
2. Pharmacological Intervention: Short-acting inhaled beta2-agonists (SABA) with/without anticholinergics (SAMA).
3. Systemic Therapy: Consider systemic corticosteroids (e.g., Prednisolone 40mg QD for 5 days) and antibiotics if increased sputum purulence/volume.
4. Respiratory Support: Early initiation of Non-invasive Ventilation (NIV/BiPAP) if respiratory acidosis (pH < 7.35 or PaCO2 > 45 mmHg).
【Heart Failure Management - 2022 AHA/ACC/HFSA Guidelines】
1. GDMT Optimization: Implementation of four pillar therapies for HFrEF patients:
- ARNI (Sacubitril/Valsartan) or ACEI/ARB
- Evidence-based Beta-blockers (Carvedilol, Bisoprolol, or Metoprolol succinate)
- Mineralocorticoid Receptor Antagonists (MRA)
- SGLT2 Inhibitors (Dapagliflozin or Empagliflozin)
2. Monitoring: Evaluate renal function (BUN/Cr), electrolytes (K+), and blood pressure titration during the stabilization phase.
【Diabetes Care - ADA 2024 Standards of Care】
1. Organ Protection Strategy: For patients with established ASCVD, Heart Failure, or CKD, prioritize SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular/renal benefit.
2. Glycemic Targets: Individualized A1c goals (usually <7% for most non-pregnant adults) balanced with hypoglycemia risk assessment.
3. Screening: Annual monitoring of UACR (Urine Albumin-to-Creatinine Ratio) and eGFR for early detection of diabetic kidney disaese.
【NP Clinical Decision Framework】
1. Initial Assessment: Focused physical examination and review of vital signs (Identify Red Flags).
2. Diagnostic Logic: Review lab results (ABG, CXR, ECG) based on evidence-based guidelines (e.g., GOLD, SSC, AHA).
3. Collaborative Decision: Propose a pre-settled order or medical plan (Pharmacological + Non-pharmacological).
4. Monitoring & Follow-up: Evaluate patient response and adjust the management plan to optimize outcomes and reduce ALOS (Average Length of Stay).
